Insights

Loading spinner
Gathering insights about AELIS FARMA

Similar companies to AELIS FARMA

AELIS FARMA Tech Stack

AELIS FARMA uses 8 technology products and services including cdnjs, Cloudflare, MySQL, and more. Explore AELIS FARMA's tech stack below.

  • cdnjs
    Content Delivery Network
  • Cloudflare
    Content Management System
  • MySQL
    Database
  • Vue.js
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • Node.js
    Programming Languages
  • All in One SEO Pack
    Search Engines
  • Apache HTTP Server
    Web Servers

Media & News

AELIS FARMA's Email Address Formats

AELIS FARMA uses at least 1 format(s):
AELIS FARMA Email FormatsExamplePercentage
F.Last@aelisfarma.comJ.Doe@aelisfarma.com
49%
FM.Last@aelisfarma.comJM.Doe@aelisfarma.com
1%
F.Last@aelisfarma.comJ.Doe@aelisfarma.com
49%
FM.Last@aelisfarma.comJM.Doe@aelisfarma.com
1%

Frequently Asked Questions

Where is AELIS FARMA's headquarters located?

Minus sign iconPlus sign icon
AELIS FARMA's main headquarters is located at 146 rue leo saignat bordeaux cedex, 33077 FR. The company has employees across 2 continents, including EuropeOceania.

What is AELIS FARMA's phone number?

Minus sign iconPlus sign icon
You can contact AELIS FARMA's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is AELIS FARMA's official website and social media links?

Minus sign iconPlus sign icon
AELIS FARMA's official website is aelisfarma.com and has social profiles on LinkedIn.

How much revenue does AELIS FARMA generate?

Minus sign iconPlus sign icon
As of December 2024, AELIS FARMA's annual revenue reached $3.8M.

What is AELIS FARMA's SIC code NAICS code?

Minus sign iconPlus sign icon
AELIS FARMA's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AELIS FARMA have currently?

Minus sign iconPlus sign icon
As of December 2024, AELIS FARMA has approximately 33 employees across 2 continents, including EuropeOceania. Key team members include Chief Executive Officer: P. V. P.Chief Operating Officer: S. M.Head Of Pharmaceutical Development: C. C.. Explore AELIS FARMA's employee directory with LeadIQ.

What industry does AELIS FARMA belong to?

Minus sign iconPlus sign icon
AELIS FARMA operates in the Biotechnology Research industry.

What technology does AELIS FARMA use?

Minus sign iconPlus sign icon
AELIS FARMA's tech stack includes cdnjsCloudflareMySQLVue.jsjQueryNode.jsAll in One SEO PackApache HTTP Server.

What is AELIS FARMA's email format?

Minus sign iconPlus sign icon
AELIS FARMA's email format typically follows the pattern of . Find more AELIS FARMA email formats with LeadIQ.

How much funding has AELIS FARMA raised to date?

Minus sign iconPlus sign icon
As of December 2024, AELIS FARMA has raised $4.9M in funding. The last funding round occurred on Jul 31, 2024 for $4.9M.

When was AELIS FARMA founded?

Minus sign iconPlus sign icon
AELIS FARMA was founded in 2013.
AELIS FARMA

AELIS FARMA

Biotechnology Researchbordeaux cedex, France11-50 Employees

Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases.
Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.
These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
Two initial drug candidates are already in clinical trials in indications with high unmet medical needs: 
•	AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022.
•	AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023.
Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies.
Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.

Section iconCompany Overview

Headquarters
146 rue leo saignat bordeaux cedex, 33077 FR
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $4.9M

    AELIS FARMA has raised a total of $4.9M of funding over 4 rounds. Their latest funding round was raised on Jul 31, 2024 in the amount of $4.9M.

  • $10M

    AELIS FARMA's revenue is in the range of $10M

Section iconFunding & Financials

  • $4.9M

    AELIS FARMA has raised a total of $4.9M of funding over 4 rounds. Their latest funding round was raised on Jul 31, 2024 in the amount of $4.9M.

  • $10M

    AELIS FARMA's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.